Streptococcus pneumoniae polysaccharides conjugated to the outer membrane protein A from Klebsiella pneumoniae elicit protective antibodies

Vaccine

Volumn 20, Issue 17-18, 2002, Pages 2174-2180

  Libon, Christine ^a   Haeuw, Jean François ^a   Crouzet, Françoise ^a   Mugnier, Chantal ^a   Bonnefoy, Jean Yves ^a   Beck, Alain ^a   Corvaïa, Nathalie ^a  

^a Centre d'Immunologie Pierre Fabre   (France)

Author keywords

Carrier protein; Conjugated vaccines; P40; Polysaccharides; Streptococcus pneumoniae

Indexed keywords

ANTIBODY; BACTERIAL POLYSACCHARIDE; BACTERIAL PROTEIN; BACTERIAL VACCINE; IMMUNOGLOBULIN G; OUTER MEMBRANE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL INFECTION; BACTERIAL STRAIN; CARBOHYDRATE ANALYSIS; CONTROLLED STUDY; DRUG CONJUGATION; DRUG MECHANISM; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; KLEBSIELLA PNEUMONIAE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROVOCATION TEST; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

ANIMALS; BACTERIAL OUTER MEMBRANE PROTEINS; FEMALE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN ISOTYPES; KLEBSIELLA PNEUMONIAE; MICE; MICE, INBRED BALB C; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; POLYSACCHARIDES; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE;

EID: 0037157262     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00149-4     Document Type: Article

References (34)

1. Evaluation of two tetravalent (ACYW135) meningococcal vaccines in infants and small children: A clinical study comparing immunogenicity of O-acetyl-negative and -positive group C polysaccharides
2. Immunogenicity of conjugate vaccines consisting of pneumococcal capsular polysaccharide types 6B, 14, 19F, and 23F and a meningococcal outer membrane protein complex
3. Polysaccharide-protein conjugates: A new generation of vaccines
4. Clinical and immunological responses to the capsular polysaccharide of Haemophilus influenzae type b alone or conjugated to tetanus toxoid in 18-23-month-old children
5. Prevention of typhoid fever in nepal with the Vi capsular polysaccharide of Salmonella typhi: A preliminary report 1 year after immunization
6. Carrier-priming leads to hapten-specific suppression
7. Epitope-specific regulation. Carrier-specific induction of suppression for IgG anti-hapten antibody responses
8. Use of prior vaccinations for the development of new vaccines
9. Preparation, characterization and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates
10. Epitopic suppression in synthetic vaccine models: Analysis of the effector mechanisms
11. Carrier-induced epitopic suppression is initiated through clonal dominance
12. Epitopic overload at the site of injection may result in suppression of the immune response to combined capsular polysaccharide conjugate vaccines
13. Chromosomal sequencing using a PCR-based biotin-capture method allowed isolation of the complete gene for the outer membrane protein A of Klebsiella pneumoniae
14. The recombinant Klebsiella pneumoniae outer membrane protein (OmpA) has carrier properties for conjugated antigenic peptides
15. Carrier properties of a protein derived from outer membrane protein A of Klebsiella pneumoniae
16. Thymus-independent and -dependent responses to polysaccharide antigens
17. Carrier-induced suppression of the antibody response to a self hapten
18. Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate for use in protein-polysaccharide conjugate vaccines and immunological reagents
19. Synthesis, characterization and immunological properties in mice of conjugates composed of detoxified lipopolysaccharides of Salmonella paratyphi A bound to tetanus toxoid, with emphasis on the role of O-acetyls
20. Carrier-induced epitopic suppression, a major issue for future synthetic vaccines
21. Increasing the sensitivity of the anthrone method for carbohydrate
22. Measurement of the humoral immune response against Streptococcus pneumoniae type 14-derived antigens by an ELISA and ELISPOT assay-based on biotin-avidin technology
23. Pneumoccal capsular polysaccharide-meningococcal outer membrane protein complex conjugate vaccines: Immunogenicity and efficacy in experimental pneumococcal otitis media
24. Characterization of a recombinant pneumolysin and its use as a protein carrier for pneumococcal type 18C conjugate vaccines
25. Epitope specificity of rabbit immunoglobulin G (IgG) elicited by pneumococccal type 23F synthetic oligosaccharide and native polysaccharide protein conjugate vaccines: Comparison with human anti-polysaccharide 23F IgG
26. The synthesis of Streptococcus pneumoniae polysaccharide-tetanus toxoid conjugates and the effect of chain length on immunity
27. Immune responses of young mice to pneumococcal type 9V polysaccharide-tetanus toxoid conjugate
28. Synthetic peptides representing T-cell epitopes act as carriers in pneumococcal polysaccharide conjugate vaccines
29. B- and T-cell immune responses to pneumococcal conjugate vaccines: Divergence between carrier- and polysaccharide-specific immunogenicity
30. Cognate stimulatory B-T-cells help recruited by glycoconjugate vaccines
31. Antibody response to pneumoccal vaccination in children younger than 5 years of age
32. Studies on vaccine control and immunogenicity of polysaccharides of Streptoccocus pneumoniae
33. CpG oligodeoxynucleotides act as adjuvants for pneumococcal polysaccharide-protein conjugate vaccines and enhance antipolysaccharide immunoglobulin G2a (IgG2a) and IgG3 antibodies
34. Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers